CIK 0001438533
- Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 262383102
- Phone
- +1 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,495,607
- in 10 filings, $79.5M under 10b5-1 plans
Net −$79,495,607. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 20 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2014-09-12 | Shkreli Martin Fmr Officer Dir 10% Sharehldr | Other acquisition · Prepaid Forward Contract (obligation to sell) | +205,000 | 205,000 | ||
| 2014-09-09 | Shkreli Martin Fmr Officer Dir 10% Sharehldr | Other acquisition · Prepaid Forward Contract (obligation to sell) | +123,000 | 123,000 | ||
| 2014-08-14 | Paley Jeffrey Director | Sale | −20,000 | $12.28 | $246K | 51,665 |
| 2014-08-08 | Plotkin Horacio Chief Medical Officer | Grant or award · Employee Stock Option | +20,000 | 20,000 | ||
| 2014-05-30 | Shkreli Martin Chief Executive Officer | Other acquisition | +50,000 | $14.62 | $731K | 3,032,680 |
| 2014-05-30 | Shkreli Martin Chief Executive Officer | Other acquisition | +126,388 | $14.62 | $1.8M | 3,159,068 |
| 2014-05-30 | Shkreli Martin Chief Executive Officer | Sale | −292,400 | $15.14 | $4.4M | 2,866,668 |
| 2014-05-28 | ASELAGE STEVE President and COO | Grant or award · Employee Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2014-04-04 | Shkreli Martin Chief Executive Officer | Purchase | +8,000 | $19.64 | $157K | 2,982,680 |
| 2014-04-03 | Shkreli Martin Chief Executive Officer | Purchase | +22,500 | $22.60 | $508K | 2,974,680 |
| 2014-04-02 | Shkreli Martin Chief Executive Officer | Purchase | +10,800 | $22.28 | $241K | 2,952,180 |
| 2014-03-24 | Shkreli Martin Chief Executive Officer | Purchase | +4,000 | $17.61 | $70K | 2,941,380 |
| 2014-03-20 | Shkreli Martin Chief Executive Officer | Purchase | +5,000 | $17.97 | $90K | 2,937,380 |
| 2014-03-19 | Shkreli Martin Chief Executive Officer | Purchase | +3,500 | $18.44 | $65K | 2,932,380 |
| 2014-03-14 | Shkreli Martin Chief Executive Officer | Purchase | +4,000 | $17.36 | $69K | 2,928,880 |
| 2014-03-11 | Shkreli Martin Chief Executive Officer | Purchase | +25,900 | $19.47 | $504K | 2,924,880 |
| 2014-03-10 | Shkreli Martin Chief Executive Officer | Purchase | +10,700 | $19.32 | $207K | 2,898,980 |
| 2014-03-07 | Shkreli Martin Chief Executive Officer | Purchase | +2,498 | $18.26 | $46K | 2,888,280 |
| 2014-03-06 | Shkreli Martin Chief Executive Officer | Purchase | +1,560 | $18.93 | $30K | 2,885,782 |
| 2014-03-05 | Shkreli Martin Chief Executive Officer | Purchase | +4,000 | $18.48 | $74K | 2,884,222 |
Page 58 of 59 · 1,174 trades